ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1585

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Disease-Modifying Antirheumatic Drugs (Dmards), Genomics and Proteomics, rheumatoid arthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or validated biomarkers that can predict response to biologic or targeted-synthetic DMARD (b/tsDMARD) therapy. This approach leads to frequent therapy discontinuation and switching, resulting in greater healthcare costs without necessarily improving patient outcomes. A blood-based molecular signature response classifier (MSRC) has been validated to predict RA patients who will be non-responders to tumor necrosis factor-alpha inhibitors (TNFi), a commonly prescribed biologic treatment for RA. This study examined the impact of treatment discontinuation and switching of b/tsDMARD therapy according to treatment selection alignment with results of the MSRC.

Methods: Analyses were conducted in the Study to Accelerate Information of Molecular Signatures (AIMS), a longitudinal, prospective clinical study of RA patients across a network of rheumatology practices in the US. Patients initiating a b/tsDMARD after MSRC testing with a 6-month follow-up visit were included. Patients were classified according to whether they initiated a TNFi or an alternative mechanism of action (altMOA), and within the TNFi-treated group, whether the MSRC detected a signature of predicted non-response (Unaligned-TNFi) or not (Aligned-TNFi). Discontinuation was defined as the termination of a drug prescribed at treatment decision, and a switch was defined by the initiation of a new b/tsDMARD. Kaplan-Meier curves were used to estimate the time to discontinuation or switch. Cox proportional hazard models were used to adjust for age, sex, and baseline clinical disease activity index (CDAI), tender joint count, and TNFi-naïve status.

Results: A total of 666 patients were included: the mean age was 56.6 (SD=13.3) years, 80% were female, baseline CDAI was 32.6 (SD=16.1), 72% were TNFi-naïve (Table 1). Most patients (72%) had a treatment decision aligned with the MSRC result, of which 39% were prescribed a TNFi. The Unaligned-TNFi group, which consisted of patients with a signature of predicted non-response to TNFi yet were placed on a TNFi anyway, had a higher proportion of discontinuation compared to the Aligned group (Fig. 1). A similar trend appeared in the proportion of patients who switched drug therapies. Adjusted analyses showed the Aligned group was less likely to discontinue treatment (Table 2. Aligned-TNFi HR=0.54, 95% CI: 0.33 – 0.86; Aligned-altMOA HR=0.63, 95% CI: 0.43 – 0.94) and less likely to switch therapy than the Unaligned-TNFi group (Table 2. Aligned-TNFi HR=0.54, 95%CI: 0.33 – 0.89; Aligned-altMOA HR=0.53, 95%CI: 0.34 – 0.81).

Conclusion: When rheumatologists selected a b/tsDMARD therapy aligned with a predictive MSRC, patients experienced less therapy discontinuation and switching than those who were treated with a TNFi when the MSRC predicted future non-response. This study further demonstrates the value of precision medicine in RA in which a treatment paradigm informed by a validated biomarker test, such as the MSRC, is used to prescribe medications.

Supporting image 1

Supporting image 2

Supporting image 3

*p-values reported from a Cox proportional hazards model with covariates statistically significantly different among groups in Table 1. None of the covariates, including age, gender, baseline disease activity measurements (CDAI, tender joint counts), or TNFi-naïve status were significant after multivariable adjustment.


Disclosures: J. Curtis, AbbVie/Abbott, Amgen, ArthritisPower, Aqtual, Bendcare, Bristol-Myers Squibb(BMS), CorEvitas, FASTER, GlaxoSmithKlein(GSK), IlluminationHealth, Janssen, Labcorp, Eli Lilly, Myriad, Novartis, Pfizer, Sanofi, Scipher, Setpoint, UCB, United Rheumatology; E. Rusli, Scipher Medicine; L. Zhang, Scipher Medicine; C. Le-Short, Scipher Medicine Corporation; A. Arnaud, Scipher Medicine; J. Withers, Scipher Medicine Corporation; S. Asgarian, Scipher Medicine.

To cite this abstract in AMA style:

Curtis J, Rusli E, Zhang L, Le-Short C, Arnaud A, Withers J, Asgarian S. Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/decreased-discontinuation-and-switching-of-b-tsdmard-therapy-in-ra-patients-when-treatment-is-aligned-with-a-molecular-signature-response-classifier-an-analysis-from-the-study-to-accelerate-informati/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-discontinuation-and-switching-of-b-tsdmard-therapy-in-ra-patients-when-treatment-is-aligned-with-a-molecular-signature-response-classifier-an-analysis-from-the-study-to-accelerate-informati/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology